
CAS 2231744-29-7
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
5 produits concernés.
MT-802
CAS :MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formule :C41H41N9O8Degré de pureté :95.93% - 97%Couleur et forme :SolidMasse moléculaire :787.822-(2-(2-(4-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)acetamide
CAS :Formule :C41H41N9O8Degré de pureté :95%Couleur et forme :SolidMasse moléculaire :787.81972-(2-(2-(4-(4-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl)Piperidin-1-Yl)Ethoxy)Ethoxy)-N-(2-(2,6-Dioxopiperidin-3-Yl)-1,3-Dioxoisoindolin-5-Yl)Acetamide
CAS :2-(2-(2-(4-(4-Amino-3-(4-Phenoxyphenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-Yl)Piperidin-1-Yl)Ethoxy)Ethoxy)-N-(2-(2,6-Dioxopiperidin-3-Yl)-1,3-Dioxoisoindolin-5-Yl)AcetamideDegré de pureté :99%Masse moléculaire :787.82g/molMT-802
CAS :<p>MT-802 is a small molecule that inhibits the ubiquitin-proteasome system. It has been shown to inhibit tumor xenografts and chronic lymphocytic leukemia in animal models. MT-802 molecule has also shown efficacy in treating autoimmune diseases, such as lupus. The drug works as a covalent inhibitor of polyubiquitin, which is involved in the process of protein degradation by proteasomes. MT-802 binds to polyubiquitin and irreversibly inhibits its function, leading to increased degradation of proteins and inhibition of tumor growth.</p>Formule :C41H41N9O8Degré de pureté :Min. 95%Masse moléculaire :787.8 g/mol



